Quick Answer
Rani Therapeutics Holdings, Inc. reported Earnings Per Share Diluted of $0.45 (loss) per share for the year ending 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +57.1% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Rani Therapeutics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $0.16 (loss) per share | Q1 2022: $0.29 per share | Q2 2022: $0.31 per share | Q3 2022: $0.33 per share | Q1 2023: $0.33 (loss) per share | Q2 2023: $0.37 (loss) per share | Q3 2023: $0.36 (loss) per share | Q1 2024: $0.29 (loss) per share | Q2 2024: $0.26 (loss) per share | Q3 2024: $0.24 (loss) per share | Q1 2025: $0.22 (loss) per share | Q2 2025: $0.18 (loss) per share | Q3 2025: $0.12 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Rani Therapeutics Holdings, Inc.'s Earnings Per Share Diluted has declined by 4.7%.
- Historical annual values: Fiscal year 2025: $0.45 (loss) per share | Fiscal year 2024: $1.05 (loss) per share | Fiscal year 2023: $1.33 (loss) per share | Fiscal year 2022: $1.28 (loss) per share | Fiscal year 2021: $0.43 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: